Enveda Biosciences
EB
Enveda Biosciences discovers and develops small-molecule medicines from compounds found in nature. Its platform combines high-throughput metabolomics with machine learning and biological data to map chemical space and identify drug leads. The company advances selected programs toward clinical development for patients with serious diseases.
Blended valuation$2B
Valuation history
Weekly blended valuation with priced funding rounds marked on the timeline.
$2.1B
blended valuationfunding round
Jul 27, 2026$920MOct 5, 2026
All rounds
9 funding rounds, newest first.
| Round | Announced | Raised | Post-money |
|---|---|---|---|
| Series E | Sep 23, 2026 | $311M | $2B |
| Series D | Sep 4, 2025 | $150M | $1B |
| Series C | Feb 26, 2025 | $20M | — |
| Series C | Nov 21, 2024 | $130M | — |
| Series B | Jun 14, 2024 | $55M | — |
Join Legion to view all 9 rounds.Sign in to Legion
Investors
28 investors across all rounds.
- TVTrue Ventures
- KIKinnevik
- LCLux Capital
- DCDimension Capital
- PIPremji Invest
- SCSurveyor Capital
- HKHenry Kravis
- BGBaillie Gifford
- CCCatalio Capital Management
- IVIA Ventures
Only Legion members can view the full investor roster. Sign in to Legion
Invest in the private markets on Legion
Registered users see full trading activity, every investor, rankings, and live deals.
Data as of Oct 16, 2026. Valuations are estimates blended from primary and secondary-market signals — not investment advice.